The COMPASS Study – Community Prevalence of SARS-CoV-2 Study (CoVPN 5002) will estimate the percentage of people affected by SARS-CoV-2 in selected communities in the United States. SARS-CoV-2 is the name of the virus that causes the coronavirus disease, called COVID-19. The COMPASS Study will evaluate the extent of COVID-19 in these communities; assess knowledge, attitudes and behaviors related to SARS-CoV-2 and COVID-19; model the potential impact of different prevention interventions; and guide future SARS-CoV-2 prevention studies and COVID-19 treatment studies in these communities. It will also provide valuable samples for important laboratory assessments related to the acquisition of SARS-CoV-2 and impact of the COVID-19 pandemic.

The study enrolled approximately 26,000 people and results are expected towards the end of 2021. CoVPN 5002 enrolled participants from communities close to research sites that have experience conducting clinical trials. All individuals provided informed consent before they joined the study. In addition to community recruitment, the survey included adults recruited from outpatient medical clinics and nursing and assisted living facilities. The goal of the recruitment strategy was to include children and adults who would provide a representative snapshot of the community. 

The COMPASS Study is being implemented by the COVID-19 Prevention Network (CoVPN). The CoVPN was formed by the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health to respond to the global pandemic. The CoVPN consists of:

The HVTN is overseeing the vaccine trials and the HPTN is overseeing the monoclonal antibody (mAb) trials in the CoVPN. The COMPASS Study is an observational study, overseen by the HPTN, and will not assess any vaccines or treatments for COVID.  

For more information on the COVID-19 Prevention Network, please visit www.PreventCOVID.org

Read more about the COMPASS Study on the FAQ page.